INTRODUCTION
============

MEDULLOBLASTOMA
---------------

Medulloblastoma, a pediatric brain tumor that arises in the cerebellum, is a devastating childhood disease. About one thousand new cases of medulloblastoma are diagnosed worldwide each year, making medulloblastoma the most common malignant pediatric brain tumor (at an incidence of 0.6 cases per 100,000 person-years) ([@b8-molcell-37-5-357-1]; [@b19-molcell-37-5-357-1]). Medulloblastoma diagnoses peak in patients of 3--5 years of age, but can occur at any age, accounting for 1% of brain tumors in adults ([@b35-molcell-37-5-357-1]; [@b63-molcell-37-5-357-1]). Medulloblastoma is treated with a combination of surgical re-section, chemotherapy, and intensive radiation to the entire cerebrospinal axis ([@b63-molcell-37-5-357-1]). While the overall five year recurrence-free survival rates are around 70--80%, response to therapy differs dramatically depending on the exact underlying molecular alterations that drive an individual patient's tumor ([@b43-molcell-37-5-357-1]; [@b88-molcell-37-5-357-1]). Different medulloblastoma subgroups, as defined by histological and/or molecular characteristics, have five year survival rates ranging from 22--95% ([@b43-molcell-37-5-357-1]).

Beyond the poor prognosis of some medulloblastoma sub-types, the urgent need for targeted therapies for medulloblastoma is further illustrated by the extremely poor quality of life experienced by medulloblastoma survivors. Nonspecific, cytotoxic therapies cause severe neurological, endocrine, and cognitive impairments in children. One year after treatment, up to 80% of children with medulloblastoma are observed to exhibit at least one major neurological symptom such as gait problems or epilepsy ([@b22-molcell-37-5-357-1]). By identifying the molecular drivers of medulloblastoma, more precise drug targets can be pursued in hopes of increasing therapeutic efficacy and decreasing side effects. The concept of targeted drugs tailored to the specific molecular alterations present in a given tumor has revolutionized our approach to drug development. While there is still much work to be done before targeted therapeutics overtake traditional modalities, successes such as imatinib for the treatment of chronic myeloid leukemia and trastuzumab for breast cancer treatment illustrate the extraordinary potential for this strategy ([@b81-molcell-37-5-357-1]). Currently, the main obstacle to developing targeted therapy for medulloblastoma is the poor understanding of the molecular alterations underlying this disease.

In response to this need, massive effort has recently been devoted to identifying and correlating genomic and transcriptomic differences among patient tumors to understand the molecular genesis of medulloblastoma. Extensive transcriptomic analysis led to the current consensus that medulloblastoma can be divided into four tumor subgroups ([@b9-molcell-37-5-357-1]; [@b42-molcell-37-5-357-1]; [@b59-molcell-37-5-357-1]; [@b72-molcell-37-5-357-1]; [@b94-molcell-37-5-357-1]). Two of these subgroups, known as the Wnt and SHH types, are named after their known mechanism of tumorigenesis. The remaining two subtypes, which are far less well understood, are denoted Groups 3 and 4. Studies from genetically engineered mouse models demonstrate that these different medulloblastoma subtypes likely arise from different cell types within the cerebellum ([@b26-molcell-37-5-357-1]; [@b36-molcell-37-5-357-1]; [@b85-molcell-37-5-357-1]; [@b104-molcell-37-5-357-1]).

Tumors driven by Wnt signaling are the least common type of medulloblastoma. Patients with Wnt-driven tumors have an excellent prognosis, with a 95--100% five year survival rate ([@b43-molcell-37-5-357-1]). Over 90% of these tumors contain a mutation in CTNNB1 (β-catenin), which drives the activation of Wnt pathway target genes. Wnt tumors have the lowest overall mutation rate of all the medulloblastoma subtypes, and at the chromosomal level, monosomy of chromosome 6 is the only consistent alteration within this subgroup ([@b12-molcell-37-5-357-1]).

The best-understood medulloblastoma subgroup is driven by alterations in the Sonic hedgehog (Shh) signaling pathway, comprising approximately 28% of medulloblastoma cases ([@b43-molcell-37-5-357-1]). Shh group tumors can result from somatic or germline mutation in Shh pathway genes such as SMO, PTCH1, SUFU, or GLI2 ([@b70-molcell-37-5-357-1]; [@b71-molcell-37-5-357-1]). This subtype has an intermediate prognosis. Some progress has been made in tailoring therapies specific for Shh-driven medulloblastomas, through the development of Shh pathway antagonists ([@b49-molcell-37-5-357-1]; [@b71-molcell-37-5-357-1]; [@b105-molcell-37-5-357-1]). However, the rapid development of resistance to these drugs has so far limited the usefulness of this therapeutic approach. This group of tumors was recently found to harbor frequent mutations in the promoter of telomerase reverse transcriptase (TERT), suggesting that a combination therapy with agents targeting Shh signaling and telomerase may be a promising avenue of research ([@b73-molcell-37-5-357-1]).

Group 3 tumors express genes involved in GABAergic/photoreceptor signaling, and have a poor prognosis (five year survival rates are 39% and 58% for infants and children, respectively) ([@b43-molcell-37-5-357-1]). Amplifications of the known oncogene MYC are exclusively found in Group 3, and are mutually exclusive with amplicons containing OTX2, a transcription factor that cooperates with MYC ([@b2-molcell-37-5-357-1]; [@b60-molcell-37-5-357-1]). While only approximately one third of Group 3 tumors amplify MYC, these tumors have by far the worst prognosis of any medulloblastoma ([@b60-molcell-37-5-357-1]). Group 3 tumors were also found to be significantly enriched for mutations that are predicted to activate TGF-β signaling ([@b60-molcell-37-5-357-1]). Two mouse models for MYC-amplified Group 3 tumors were recently developed, yielding an important tool for the study of these tumors ([@b36-molcell-37-5-357-1]; [@b64-molcell-37-5-357-1]).

Group 4 is the most frequently observed medulloblastoma subtype comprising one third of all tumors, with an intermediate prognosis (5 year survival rate of approximately 70%) ([@b43-molcell-37-5-357-1]). Group 4 tumors feature frequent mutation in chromatin modification genes, and express many genes involved in neuronal differentiation ([@b33-molcell-37-5-357-1]; [@b43-molcell-37-5-357-1]). Some Group 4 tumors amplify N-MYC, while the most frequent amplification (10% of Group 4 tumors) is the duplication of synphilin-1 (SNCAIP), a protein previously implicated in neurodegenerative disease ([@b60-molcell-37-5-357-1]). One study suggested that NF-κB signaling may be implicated in Group 4 tumorigenesis, as several mutations were found in NF-κB pathway genes ([@b60-molcell-37-5-357-1]).

After transcriptomic studies firmly established that these subgroups represent four distinct disease entities falling under the umbrella of medulloblastoma, the scientific community next turned to genomic sequencing to better understand the molecular pathogenesis underlying each medulloblastoma subtype. We now have a wealth of information regarding the somatic mutations which occur in the medulloblastoma genome, thanks to major sequencing and copy number variation studies which were recently published ([@b33-molcell-37-5-357-1]; [@b60-molcell-37-5-357-1]; [@b66-molcell-37-5-357-1]; [@b77-molcell-37-5-357-1]). The implications of these massive and complex datasets are just now beginning to be understood.

One interesting observation is that many of the genes observed to be mutated in medulloblastoma are RNA binding proteins. For example, the authors of one study note that up to 15% of all medulloblastomas contain somatic mutations predicted to disrupt the function of at least one RNA helicase ([@b66-molcell-37-5-357-1]). RNA binding proteins are especially interesting as drivers of oncogenesis because of their ability to alter the expression of large numbers of downstream genes through multiple processes: they can regulate splicing, translation efficiency, and mRNA localization, modification, and decay. In this review, we will highlight RNA-binding proteins which are known or suspected to contribute to medulloblastoma development.

RNA-BINDING PROTEINS
--------------------

RNA-binding proteins are a large group of regulators (800--1,000 in humans) that influence RNA processing, localization, storage, degradation, and translation efficiency ([@b6-molcell-37-5-357-1]; [@b27-molcell-37-5-357-1]; [@b103-molcell-37-5-357-1]) Their combined impact is thought to account for as much as 30% of protein expression variation ([@b86-molcell-37-5-357-1]; [@b98-molcell-37-5-357-1]). Many RNA binding proteins regulate protein expression from a specific subset of mRNA transcripts with a related cellular function, which can be a powerful post-transcriptional mechanism to regulate cellular phenotype. RNA binding proteins often interact with the 5′ or 3′ untranslated regions (UTRs) of mRNAs, which contain a wealth of regulatory sequences that influence translational efficiency and mRNA stability ([@b102-molcell-37-5-357-1]). The importance of regulation of protein homeostasis by RNA binding proteins is highlighted by the numerous Mendelian genetic diseases caused by mutations in RNA binding proteins ([@b7-molcell-37-5-357-1]).

RNA binding domains can be found in a wide variety of proteins; relevant domain families include the RNA recognition motif (RRM), CCCH Zinc finger, Winged-helix, Ferredoxin like RNA-binding, and K homology domains ([@b54-molcell-37-5-357-1]; [@b103-molcell-37-5-357-1]). However, a number of recent studies of the mRNA-bound proteome in yeast and human cells demonstrate that many proteins without canonical RNA binding domains can also bind RNA, suggesting that we have only begun to understand this widespread and essential biochemical function ([@b4-molcell-37-5-357-1]; [@b6-molcell-37-5-357-1]; [@b39-molcell-37-5-357-1]; [@b82-molcell-37-5-357-1]; [@b96-molcell-37-5-357-1]).

One family of RNA binding proteins that contains several proteins suspected to contribute to medulloblastoma tumorigenesis is the DEAD-box RNA helicase family. These proteins share a common set of domains within the helicase core, including the namesake D-E-A-D sequence in motif II ([@b48-molcell-37-5-357-1]). The human genome encodes approximately 30 DEAD-box RNA helicases, which metabolize ATP to unwind RNA and/or remodel RNA-protein complexes ([@b68-molcell-37-5-357-1]). These proteins can also clamp onto RNA, thus serving as a scaffold for the assembly of larger RNA-protein complexes ([@b50-molcell-37-5-357-1]). RNA helicases perform a diverse variety of functions in the cell, and mutations in these genes have previously been linked to cancer ([@b1-molcell-37-5-357-1]).

MSI1
----

Musashi1 (MSI1) was originally identified in *Xenopus* and *Drosophila*, and later in mammals, as an RNA binding protein essential for proper development of the nervous system ([@b57-molcell-37-5-357-1]; [@b74-molcell-37-5-357-1]; [@b79-molcell-37-5-357-1]). MSI1 has two tandem RNA recognition motifs ([Fig. 1](#f1-molcell-37-5-357-1){ref-type="fig"}), and functions to maintain the proliferation and renewal of multi-potent neural stem/progenitor cells. Staining for MSI1 expression can be used as a stem cell marker ([@b78-molcell-37-5-357-1]). In addition to neural stem cells, MSI1 expression has been shown to define populations of multi-potent cells in a number of other niches, including in ducts in the breast, crypts in the intestines, and hair follicles ([@b37-molcell-37-5-357-1]; [@b91-molcell-37-5-357-1]; [@b99-molcell-37-5-357-1]). MSI1 can act as a positive or negative regulator of translation by binding to the 3'UTR of a target gene's mRNA, with an apparent preference for sequences with (G/A)U~1--3~AGU repeats ([@b32-molcell-37-5-357-1]; [@b97-molcell-37-5-357-1]). The most well-characterized function of MSI1 is enhancement of Notch pathway signaling through blocking translation of Numb, which functions to repress this pathway ([@b32-molcell-37-5-357-1]). Only a few MSI1 target mRNAs have been validated to date, including Numb, CDKN1A, doublecortin, and Robo3 ([@b5-molcell-37-5-357-1]; [@b30-molcell-37-5-357-1]; [@b32-molcell-37-5-357-1]; [@b44-molcell-37-5-357-1]). However, recent research indicates that MSI1 regulates hundreds of targets through post-transcriptional mechanisms, affecting numerous critical cellular processes including proliferation, differentiation, and apoptosis ([@b80-molcell-37-5-357-1]; [@b97-molcell-37-5-357-1]).

Medulloblastoma is considered an embryonal brain tumor as its cells resemble neural stem/progenitor cells both in general appearance and differentiation potential ([@b18-molcell-37-5-357-1]; [@b28-molcell-37-5-357-1]). Sub-populations of stem-like medulloblastoma cells have been found within the tumor as a whole that are especially resistant to conventional therapy ([@b29-molcell-37-5-357-1]). The importance of MSI1 in the maintenance of neural stem cells lead to the hypothesis that MSI1 might also play a role in medulloblastoma tumorigenesis.

The first evidence for such a role came from studies showing that MSI1 is highly expressed in a number of brain tumors, including medulloblastoma ([@b41-molcell-37-5-357-1]; [@b58-molcell-37-5-357-1]; [@b95-molcell-37-5-357-1]). Analysis of MSI1 across a large cohort of medulloblastoma samples from human patients demonstrated that high MSI1 expression is a strong indicator of poor prognosis ([@b97-molcell-37-5-357-1]). MSI1 was found to be expressed in all four medulloblastoma subtypes, with particularly high expression in Group 3 and 4 tumors ([@b97-molcell-37-5-357-1]). Another study used suppression subtractive hybridization to identify MSI1 as a gene deregulated in tumors derived from a mouse model of medulloblastoma, as compared to the normal mouse cerebellum ([@b107-molcell-37-5-357-1]). The overexpression of MSI1 at both the mRNA and protein levels in human tumors and tumors from genetically engineered mouse models suggests that MSI1 plays an important role in medulloblastoma tumorigenesis. In medulloblastoma, MSI1 appear to exert its protumorigenic effect through overexpression of the wild-type protein, as no evidence of somatic mutations in medulloblastoma have been found to date ([@b20-molcell-37-5-357-1]).

Evidence for a causal role of MSI1 in medulloblastoma came from studies of the widely used medulloblastoma cell line DAOY. Knockdown of MSI1 in DAOY cells diminished their ability to grow as neurospheres and to form colonies in soft agar, indicating that MSI1 helps to maintain stem cell-like properties in tumor cells ([@b56-molcell-37-5-357-1]; [@b80-molcell-37-5-357-1]). Analysis of brain tumor cells in which MSI1 was knocked down resulted in impairment of several essential signaling pathways, including Notch and PI(3) kinase-Akt ([@b56-molcell-37-5-357-1]).

Further insight into the mechanism by which MSI1 regulates the growth and survival of medulloblastoma cells was provided by studies which investigated target mRNAs bound and regulated by MSI1. Reverse immunoprecipitation combined with microarray technology was used to identify genes whose mRNAs are bound by MSI1 in medulloblastoma cells ([@b97-molcell-37-5-357-1]). This list of genes was found to significantly overlap with similar experiments performed in glioblastoma cells, suggesting that MSI1 may promote tumorigenesis in a variety of tumor types. Genes regulated by MSI1 in medulloblastoma were significantly enriched for a number of cancer-related functions, including cell proliferation, apoptosis, and differentiation ([@b97-molcell-37-5-357-1]).

Proof-of-principle experiments have tested the utility of targeting MSI1 as a therapeutic measure for medulloblastoma. Treatment of mice bearing xenograft tumors derived from human medulloblastoma cell lines with siRNAs targeting MSI1 resulted in tumor regression and prolonged survival ([@b97-molcell-37-5-357-1]). Therapies that target MSI1 may also be of use for other types of cancer as well. Knockdown of MSI1 has been shown to reduce tumor size and increase overall survival in animal models of several other tumors, including glioblastoma and colorectal cancer ([@b56-molcell-37-5-357-1]; [@b93-molcell-37-5-357-1]). Other tumors have also been shown to overexpress MSI1 in comparison to normal tissue, although the reliance of these tumors on MSI1 expression has in most cases not yet been determined ([@b50-molcell-37-5-357-1]; [@b53-molcell-37-5-357-1]; [@b55-molcell-37-5-357-1]; [@b100-molcell-37-5-357-1]; [@b101-molcell-37-5-357-1]).

DDX3X
-----

One of the strongest emerging candidate RNA binding proteins with a potential role in medulloblastoma pathogenesis is the DEAD-box RNA helicase DDX3X. Human DDX3X was originally discovered through its interaction with proteins from the hepatitis C virus (HCV) ([@b62-molcell-37-5-357-1]). DDX3X has since been found to play contrasting roles in viral infection, being manipulated by viruses such as HCV, influenza, and human immunodeficiency virus (HIV) to facilitate viral infection ([@b34-molcell-37-5-357-1]; [@b62-molcell-37-5-357-1]; [@b106-molcell-37-5-357-1]), while also serving to activate the interferon-based innate immune response ([@b85-molcell-37-5-357-1]; [@b90-molcell-37-5-357-1]). However, anti-viral defense is only a small part of the cellular function of DDX3X. DDX3X also regulates the translation and localization of numerous mRNAs to control cellular processes that are related to cancer, including apoptosis signaling and the cell cycle ([@b10-molcell-37-5-357-1]; [@b92-molcell-37-5-357-1]).

Recent work has identified both general as well as specific roles of DDX3X in translation regulation. DDX3X may augment translation by resolving secondary structures of long 5′-untranslated regions in the mRNA during ribosome scanning ([@b46-molcell-37-5-357-1]). DDX3X also binds the translation initiation factor EIF4F, allowing for translation of specific mRNAs ([@b89-molcell-37-5-357-1]). In terms of specific targets, one study has shown that DDX3X regulates cell growth through translational control of cyclin E1 and other cell cycle regulators ([@b47-molcell-37-5-357-1]). A precise binding motif is as yet unknown, and specificity may instead result from interactions with other RNA binding proteins. On the level of general (non-targeted) translational regulation, DDX3X assists with ribosome assembly ([@b25-molcell-37-5-357-1]).

Three recent, independent large-scale genomic sequencing studies identified frequent somatic mutations in DDX3X in medulloblastoma ([@b33-molcell-37-5-357-1]; [@b66-molcell-37-5-357-1]; [@b77-molcell-37-5-357-1]). In fact, DDX3X was the second-most frequently mutated gene, following only CTNNB1 (the driver mutation for Wnt pathway tumors) ([Table 1](#t1-molcell-37-5-357-1){ref-type="table"}). DDX3X mutations are strongly enriched in the Wnt medulloblastoma subtype, with approximately half of Wnt tumors bearing a mutation in DDX3X ([@b66-molcell-37-5-357-1]). DDX3X mutations are also seen in some Shh tumors. DDX3X mutations observed in medulloblastoma were point mutations, not truncations, and structural analysis suggests nearly all of the mutations identified occurred within the RNA helicase domain or RNA binding interface ([Fig. 1](#f1-molcell-37-5-357-1){ref-type="fig"}) ([@b33-molcell-37-5-357-1]; [@b66-molcell-37-5-357-1]; [@b77-molcell-37-5-357-1]). These findings suggest that the DDX3X mutations alter the protein's function, likely in the realm of a modified protein-RNA interaction, as opposed to a complete loss of function.

To validate a potential role played by DDX3X in medulloblastoma, DDX3X was knocked down in lower rhombic lip progenitor cells, a cell population which is thought to be the cell-of-origin for Wnt-driven medulloblastomas ([@b26-molcell-37-5-357-1]). DDX3X depletion significantly reduced the self-renewal rate of these cells, supporting the hypothesis that DDX3X promotes the development of medulloblastoma ([@b77-molcell-37-5-357-1]).

The prevalence of DDX3X mutations in Wnt-driven medulloblastomas suggests that DDX3X mutations exert their protumorigenic effect by promoting Wnt signaling. This hypothesis is supported by the finding that co-transfection of mutant beta-catenin (with an activating mutation found in \> 90% of Wnt-driven medulloblastomas) alongside mutant DDX3X enhanced transcription from the TOP-FLASH promoter, suggesting that these tumor-derived DDX3X mutants act to further enhance Wnt signaling in the presence of stabilized beta-catenin ([@b66-molcell-37-5-357-1]). One recent study showed that DDX3X can play a direct role in the promotion of Wnt signaling in mammalian cells, by acting as a regulatory subunit of casein kinase 1 (CK1) ([@b13-molcell-37-5-357-1]). When bound to CK1, DDX3X activates phosphorylation of disheveled (DVL2), thereby promoting assembly of a multiprotein complex that results in the stabilization of beta-catenin and the activation of Wnt signaling ([@b13-molcell-37-5-357-1]). These findings strongly support the hypothesis that the DDX3X mutations observed in medulloblastoma enhance Wnt signaling by augmenting the binding of DDX3X to CK1, thereby further enhancing the stability of mutant beta-catenin and amplifying the transcription of Wnt target genes. In this case, it appears that DDX3X exerts its regulatory effect via protein-protein, rather than protein-mRNA interactions.

One important remaining question is the role played by the RNA binding function of DDX3X in Wnt signaling and medulloblastoma tumorigenesis. The finding that all of the DDX3X mutations are found in locations related to RNA binding suggests that alterations in the RNA binding and/or helicase function of DDX3X may contribute to the pro-tumorigenic function. However, this conjecture has to be reconciled with the finding that the promotion of Wnt signaling via CK1 is independent of both the RNA binding and ATPase activity of DDX3X ([@b13-molcell-37-5-357-1]). One possibility is that the RNA binding/helicase function(s) of DDX3X compete with its role as a regulator of CK1 phosphorylation. Destruction of the RNA binding capability of DDX3X may therefore free up more protein to bind CK1, thereby ultimately promoting Wnt signaling. This mechanism may involve differential localization of different pools of DDX3X, depending on whether or not it is bound to RNA. However, it is also possible that the RNA binding function of DDX3X directly contributes to tumorigenesis independent of Wnt signaling, through its roles in cell cycle control, regulation of cell growth, and apoptotic signaling ([@b47-molcell-37-5-357-1]; [@b65-molcell-37-5-357-1]; [@b84-molcell-37-5-357-1]).

DDX31
-----

DDX31 is another DEAD-box RNA helicase that was found to be mutated in multiple tumors in a medulloblastoma sequencing study ([@b77-molcell-37-5-357-1]). DDX31 is a protein conserved across eukaryotes, but it has not been well-studied. No DDX31-mRNA interactions have been verified for individual targets. DDX31 and its yeast homolog DBP7 participate in the transcription of rRNA genes and the assembly of the 60S ribosome subunit ([@b14-molcell-37-5-357-1]; [@b23-molcell-37-5-357-1]). DDX31 was characterized in humans as a nucleolar protein consistently upregulated in renal cell carcinoma ([@b23-molcell-37-5-357-1]). In mammalian cells, DDX31 binds nucleophosmin (NPM), blocking an interaction between NPM and HDM2, the E3 ubiquitin ligase for p53 ([@b23-molcell-37-5-357-1]). Depletion of DDX31 restores the NPM-HDM2 interaction, ultimately resulting in stabilization of p53. Either of these cellular functions could plausibly contribute to a potential role for DDX31 in medulloblastoma tumorigenesis, but further study is needed.

Multiple mutations in DDX31 were observed in the medulloblastoma genome sequences. DDX31 deletions were observed in three different Group 4 medulloblastomas (as well as one tumor of unknown subtype). DDX31 was located in the breakpoint of this focal deletion, which also encompassed the genes AK8 and TSC1 ([@b77-molcell-37-5-357-1]). The DDX31 deletions occurred simultaneously with amplification of the OTX2 locus, a known medulloblastoma oncogene ([@b2-molcell-37-5-357-1]; [@b15-molcell-37-5-357-1]). This finding suggests that DDX31 mutation (either by deletion or truncation) may cooperate with the oncogenic role of OTX2. Several other tumors in the medulloblastoma study contained DDX31 missense mutations ([@b77-molcell-37-5-357-1]). The frequency with which DDX31 mutations occur, along with its essential functions in ribosome biogenesis and p53 regulation, suggest that DDX31 will be a fruitful target for further study of the signaling pathways involved in medulloblastoma.

CCAR1
-----

Two of the three major medulloblastoma genome sequencing studies identified mutations in cell division cycle and apoptosis regulator 1 (CCAR1/CARP1) ([@b66-molcell-37-5-357-1]; [@b77-molcell-37-5-357-1]). CCAR1 contains a cold-shock RNA binding domain, and associates with cytoplasmic RNA structures known as stress granules ([@b40-molcell-37-5-357-1]; [@b75-molcell-37-5-357-1]). CCAR1 was originally discovered as a stress-induced protein that represses expression of a number of cell cycle regulatory genes, including cyclin B1 and c-Myc ([@b75-molcell-37-5-357-1]). In addition to its role in regulation of the cell cycle, CCAR1 also mediates signaling for apoptosis ([@b21-molcell-37-5-357-1]; [@b75-molcell-37-5-357-1]; [@b76-molcell-37-5-357-1]), and serves as a co-factor to recruit the Mediator complex to several nuclear receptors to activate transcription of downstream genes ([@b38-molcell-37-5-357-1]). The multiple mutations in the CCAR1 gene in sequencing studies and its involvement in several cancer-related processes render the gene an excellent candidate for a potential role in medulloblastoma tumorigenesis.

Although a direct role for CCAR1 in medulloblastoma has not yet been established, one study has examined the potential of CCAR1 as a therapeutic target in medulloblastoma ([@b38-molcell-37-5-357-1]). Two human medulloblastoma cell lines were treated with small molecule inhibitors of CCAR1, known as CARP-1 Functional Mimetics (CFMs), which are designed to block the interaction of CCAR1 with the APC-2 subunit of the anaphase promoting complex (APC/C) ([@b67-molcell-37-5-357-1]). Inhibition of CCAR1 with the CFMs reduced cell proliferation, stimulated apoptosis, and repressed migration, colony formation, and invasion of human medulloblastoma cells ([@b3-molcell-37-5-357-1]). These results provide further support to the hypothesis that CCAR1 may be an essential gene for the development of medulloblastoma, and an excellent target for therapeutic strategies.

CONCLUSION
==========

Mounting evidence from studies of patient medulloblastoma samples and genetically engineered mouse models suggests that several RNA binding proteins play a role in the development of medulloblastoma.This diverse class of proteins is able to influence cellular phenotypes through both their protein-RNA and protein-protein interaction activities. Because RNA binding proteins often regulate the expression of numerous other proteins, the study of these master regulators has the potential to shed light on the pathways essential for the growth of these tumors. The identification of numerous mutations in RNA binding proteins not previously known to contribute to brain tumor pathogenesis demonstrates that there is still much work to be done in this field. As even more -omics level studies are completed, such as epigenetics ([@b16-molcell-37-5-357-1]) and proteomics ([@b17-molcell-37-5-357-1]) analysis, our understanding of the mechanisms of medulloblastoma tumorigenesis will be further enriched.

The RNA binding proteins described above are only few examples of the many putative regulators of medulloblastoma tumorigenesis. A large-scale cross-study analysis of aberrantly expressed RNA-binding proteins identified twelve proteins specifically up-regulated in the DAOY medulloblastoma cell line, providing candidates for further analysis ([@b24-molcell-37-5-357-1]). Among these candidates are several genes which have been linked to cancer in various capacities, including the RNA binding protein NONO/p54 ([@b11-molcell-37-5-357-1]; [@b83-molcell-37-5-357-1]), and the RNA helicase DHX9. ATP-dependent RNA helicases, such as DDX3X and DDX31 mentioned in this review, as well as DHX9, are particularly interesting targets for future medulloblastoma research because of their potential as druggable targets.

Small molecule drugs aimed at inhibiting DEAD-box RNA helicases are currently in various stages of development, mostly as anti-viral therapies (as RNA helicases often serve as cellular co-factors for viral infections) ([@b45-molcell-37-5-357-1]; [@b52-molcell-37-5-357-1]; [@b69-molcell-37-5-357-1]). For other RNA binding proteins, the promise of directly targeted therapies is more limited, although the discovery of small molecule inhibitors of CCAR1 function does provide some hope. There are still significant barriers to be overcome in the development of RNAi-based therapeutics, and in the absence of other enzymatic functions, inhibitory small molecules will also likely be difficult to develop ([@b108-molcell-37-5-357-1]). Perhaps the real promise of studying the function of RNA binding proteins in medulloblastoma lies in their role as master regulators of tumorigenic processes. By mapping the genes regulated by these RNA binding proteins, we gain tremendous insight into the pathways by which medulloblastoma cells proliferate and survive ([@b97-molcell-37-5-357-1]).
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![Domain structures of selected RNA binding proteins. Vertical lines above the protein represent point mutations identified in medulloblastoma sequencing studies ([@b33-molcell-37-5-357-1]; [@b66-molcell-37-5-357-1]; [@b77-molcell-37-5-357-1]). Red lines = residues with mutations identified in multiple tumors. X = truncating mutation. RRM = RNA recognition motif, DEAD = DEAD/DEAH box RNA helicase domain, Hel_C = helicase C domain, S1L = S1-like RNA binding domain, DBC1 = domain found in DBC1, SAP = SAF-A/B, Acinus and PIAS DNA/RNA binding motif. Domain annotation as predicted by InterPro ([@b31-molcell-37-5-357-1]).](molcell-37-5-357-1f1){#f1-molcell-37-5-357-1}

###### 

Most frequently mutated genes in medulloblastoma

  Gene      Description                                                                                         \# mutations   Subgroup
  --------- --------------------------------------------------------------------------------------------------- -------------- --------------
  CTNNB1    Beta-catenin                                                                                        29             Wnt
  DDX3X     DEAD (Asp-Glu-Ala-Asp) box helicase 3, X-linked                                                     25             Wnt & Shh
  KMT2D     Lysine (K)-specific methyltransferase 2D (MLL2)                                                     19             all
  PTCH1     Patched 1                                                                                           18             Shh
  SMARCA4   SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4   18             Wnt, Group 3
  KDM6A     Lysine (K)-specific demethylase 6A                                                                  16             Group 4

Mutation data were tabulated from three medulloblastoma genome sequencing studies ([@b33-molcell-37-5-357-1]; [@b66-molcell-37-5-357-1]; [@b77-molcell-37-5-357-1]). Subgroup = the subgroup(s) in which mutations most frequently occur. The top six most frequently mutated genes are listed.
